Final-Program-ATS-2023-AP.vp

238

TUESDAY • MAY 23

P154 The microRNA-mediated Changes in Pulmonary Fibroblasts of Chronic Obstructive Pulmonary Disease/ M.-J. Tsai, Kaohsiung, Taiwan P155 Utilizing Veterans Health Affairs (VHA) Database to Evaluate Inhibition of IL-17a on Rates of Chronic Obstructive Pulmonary Disease (COPD) Hospitalization Through Matched Cohort Analysis; a Hypothesis Generating Study/ C.B. Smith, Kansas City, KS P156 Cigarette Smoke Delays Murine Innate Immune Response Against X31 Influenza Infection/ J.R. Vlasma, Groningen, Netherlands P157 Affect of Regional and Gender Disparities on Mortality Related to Chronic Obstructive Pulmonary Disease/ S. Chaparala, Athens, GA P158 Systematic Literature Review to Determine Herpes Zoster Incidence in Patients With Chronic Respiratory Diseases in the European Union, Switzerland, and the United Kingdom/ A. Marijam, Wavre, Belgium P159 Lactoperoxidase a Key Player in Immunity and Inflammation Upon HIV Infection and Cigarette Smoke Exposure/ M.J. Santiago, Miami, FL P160 Identification of Stable and Suppressive Murine Regulatory T Cell Subsets to Optimize Therapeutic Potential in COPD/ C.M. Freeman, Ann Arbor, MI P161 Elevated Sputum Group 2 Innate Lymphoid Cells Indicates Clinical Severity of Chronic Obstructive Pulmonary Disease and Involves IL-17A Plasticity/ A. Linderholm, Davis, CA Pro-inflammatory CD28nullCD8+ T Lymphocytes in Patients With COPD: The Spillover Hypothesis Explained?/ G. Hodge, Adelaide, Australia P163 Blood Gene Expression and Immune Cell Subtypes Associated With COPD Exacerbations/ M.H. Ryu, Boston, MA P164 Increased Frequency of the M3 SERPINA1 Variant for AAT in Patients With COPD/ F. Kueppers, Philadelphia, PA P162 BLTR1 Is Decreased in Steroid Resistant

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

C33

ADVANCES AND UNSOLVED MYSTERIES IN COPD

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P143 Gene Expression Signature of Serpina1 Z Allele Dosage in Lung Epithelial Cells/ J. Morrow, Boston, MA P144 Regulatory T Cells Expressing Toll-like Receptor 2 in Blood From Smokers With Stable Chronic Obstructive Pulmonary Disease/ A. Linden, Stockholm, Sweden P145 Proton Pump Inhibitor-treatment of Gastroesophageal Reflux in Asthma-COPD Overlap Lessens Risk of Exacerbations More Than in Asthma Alone/ B. Patchett, Philadelphia, PA P146 Diurnal Description of Alpha 1 Antitrypsin Levels and Other Inflammatory Markers in Healthy Humans and Alpha 1 Antitrypsin Deficiency Patients/ L. Alhaddah, Dublin, Ireland P147 Circadian Protein Localisation in Monocytes of Severe Alpha 1 Antitrypsin Deficiency/ L. Alhaddah, Dublin, Ireland P148 The Swedish Broncho-Scapis Cohort: Characterization of Chronic Airflow Limitation in Adult Never-Smokers/ T. Pincikova, Stockholm, Sweden P149 Phenotypes of Blood and Sputum Eosinophils in Chronic Obstructive Pulmonary Disease and Asthma/ K. Mycroft, Warszawa, Poland P150 Blood Eosinophil Count Variabilityin Chronic Obstructive Pulmonary Disease and Severe Asthma/ Y. Abe, Sapporo, Japan P151 Positive Microbiologic Studies in Hospitalizations for COPD Exacerbation Are Associated With Longer Length of Stay and Increased Risk of Discharge to Skilled Nursing Facility/ M. Burnim, Baltimore, MD P152 Evaluation of Asthma-chronic Obstructive Pulmonary Disease Overlap Using a Mouse Model of Pulmonary Disease/ J. Hur, Seoul, Korea, Republic of P153 Characteristic of Patients With Obstructive Lung Disease From Tikur Anbessa Specialized Hospital (TASH) Addis Ababa Ethiopia/ A.B. Binegdie, Addis Ababa, Ethiopia

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

C34

SARCOIDOSIS, FIBROSIS, AND PROTEINOSIS - OH MY!

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

ATS 2023 • Washington, DC